Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. reported strong financial performance for the fiscal year ended December 31, 2025, with total revenues reaching $1.40 billion. The company achieved significant profitability, reporting operating income of $469.0 million and net income of $316.9 million, resulting in basic and diluted earnings per share of $3.00. Operating performance was impacted by substantial one-time expenses, including $284.9 million for acquired in-process research and development and a $48.7 million impairment of intangible assets. Despite these charges, the company demonstrated robust cash generation, with net cash provided by operating activities totaling $651.6 million. The balance sheet reflects a highly leveraged position following strategic acquisitions, with long-term debt of $2.14 billion against total stockholders' equity of $48.8 million. Total assets grew to $2.53 billion, bolstered by $580.4 million in goodwill and $981.5 million in intangible assets. The company actively managed its capital structure through debt refinancing and share repurchases totaling $342.4 million during the period.

Key Takeaways